MarketCapExport financials
Matinas BioPharma Holdings (MTNB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Matinas BioPharma Holdings MTNB
$ 1.52
-10.59%
Facebook
X
Telegram
Matinas BioPharma Holdings Financial Ratios 2025-2011 | MTNB
Annual Financial Ratios Matinas BioPharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.3 | -0.1 | -0.1 | -4.6 | -9.1 | -12.9 | -11.5 | -6.8 | -6.7 | -16.5 | -3.4 | -1.6 | - | - | - |
P/S |
- | - | 1.5 | 30.6 | 6432.7 | 1834.2 | 2231.0 | 802.8 | 695.1 | - | 158.8 | - | - | - | - |
EPS |
-2 | -5.0 | -5.3 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.4 | -0.2 | -0.2 | -0.3 | -0.2 | - | - |
EV (Enterprise Value) |
1.12 M | 346 K | 2.68 M | 98.9 M | 200 M | 285 M | 185 M | 87.5 M | 100 M | 124 M | 30 M | 14.6 M | -9.98 M | - | - |
EBITDA per Share |
-1.27 | -4.98 | -5.38 | -0.11 | -0.12 | -0.118 | -0.125 | -0.147 | -0.181 | -0.142 | -0.192 | -0.325 | - | - | - |
EV/EBITDA |
-0.2 | -0.0 | -0.1 | -4.1 | -8.1 | -11.9 | -9.8 | -5.8 | -5.9 | -14.8 | -2.8 | -1.3 | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | 0.5 | 4.39 | -1.68 | -0.87 | -0.12 | 0.09 | 0.99 | -0.08 | 0.01 | - | - | - |
P/B |
0.6 | 0.3 | 0.1 | 2.7 | 4.0 | 4.6 | 6.1 | 6.0 | 9.7 | 17.6 | 5.1 | 7.2 | - | - | - |
P/CF |
-0.4 | -0.2 | -0.1 | -5.1 | -13.9 | -16.7 | -13.8 | -8.9 | -8.4 | -20.5 | -3.9 | -1.9 | - | - | - |
ROE % |
-214.18 | -319.51 | -119.20 | -57.31 | -44.35 | -35.22 | -52.56 | -87.25 | -144.98 | -106.28 | -150.44 | -458.78 | - | - | - |
ROA % |
-143.52 | -191.84 | -91.39 | -46.85 | -37.97 | -31.63 | -43.17 | -70.62 | -107.37 | -77.41 | -108.68 | -304.07 | - | - | - |
ROCE % |
-121.15 | -246.55 | -105.71 | -60.67 | -43.41 | -35.91 | -50.94 | -85.64 | -135.28 | -98.63 | -136.19 | -466.52 | - | - | - |
Current Ratio |
3.0 | 2.5 | 4.3 | 5.5 | 6.9 | 17.3 | 9.7 | 4.6 | 3.6 | 3.2 | 3.2 | 2.5 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Matinas BioPharma Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.03 | -0.3 | - | -0.4 | -1.03 | -0.33 | - | -0.85 | -1.15 | -1.34 | - | -1.39 | -0.03 | -0.03 | - | -0.03 | -0.03 | -0.03 | - | -0.03 | -0.02 | -0.03 | - | -0.03 | -0.03 | -0.03 | - | -0.03 | -0.03 | -0.04 | - | -0.03 | -0.04 | -0.05 | - | -0.04 | -0.04 | -0.25 | - | -0.11 | -0.03 | -0.04 | - | -0.04 | -0.04 | -0.07 | - | -0.08 | -0.08 | -0.07 | - | -0.1 | -0.03 | -0.01 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.36 | -0.3 | - | -0.29 | -0.36 | -0.38 | - | -0.85 | -1.15 | -1.34 | - | -1.39 | -0.03 | -0.03 | - | -0.02 | -0.03 | -0.04 | - | -0.03 | -0.02 | -0.03 | - | -0.03 | -0.03 | -0.03 | - | -0.03 | -0.03 | -0.03 | - | -0.03 | -0.04 | -0.04 | - | -0.04 | -0.04 | -0.05 | - | -0.03 | -0.03 | -0.04 | - | -0.04 | -0.04 | -0.07 | - | -0.08 | -0.08 | -0.07 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-224.73 | -182.03 | -118.47 | -145.56 | -151.78 | -123.45 | -97.04 | -123.19 | -117.86 | -104.82 | -64.81 | -78.95 | -66.62 | -57.40 | -40.50 | -52.24 | -45.71 | -39.34 | -26.80 | -35.35 | -32.42 | -32.72 | -25.27 | -38.60 | -40.17 | -43.62 | -35.70 | -53.89 | -61.69 | -77.04 | -64.78 | -96.56 | -115.52 | -136.48 | -111.01 | -136.73 | -127.66 | -121.91 | -79.82 | 37.10 | 212.68 | 85.53 | 116.92 | 574.75 | 915.66 | 307.03 | 456.89 | 442.98 | -18.13 | -477.03 | -18.25 | -13.90 | -3.28 | -1.07 | - | - | - | - | - | - | - | - |
ROA % |
-167.18 | -108.18 | -75.47 | -96.25 | -103.92 | -78.33 | -64.57 | -82.38 | -76.02 | -52.54 | -52.54 | -64.03 | -55.01 | -47.91 | -33.50 | -43.71 | -39.07 | -34.62 | -23.90 | -31.58 | -29.28 | -29.55 | -22.69 | -33.64 | -34.27 | -36.43 | -29.32 | -44.04 | -50.20 | -62.50 | -52.43 | -75.97 | -88.76 | -102.82 | -82.22 | -100.94 | -93.95 | -89.31 | -58.14 | 26.33 | 153.31 | 61.60 | 84.46 | 387.90 | 606.88 | 194.56 | 302.81 | 289.96 | -16.50 | -320.93 | -16.87 | -12.85 | -3.03 | -0.99 | - | - | - | - | - | - | - | - |
ROCE % |
-111.54 | -109.84 | -58.19 | -81.93 | -89.27 | -110.75 | -90.86 | -113.95 | -109.80 | -98.59 | -58.05 | -70.85 | -60.36 | -55.61 | -40.25 | -51.19 | -45.60 | -42.06 | -27.21 | -35.53 | -33.15 | -35.35 | -26.29 | -38.57 | -42.42 | -44.91 | -35.50 | -52.77 | -60.40 | -72.32 | -61.27 | -93.18 | -113.13 | -135.23 | -111.14 | -136.80 | -127.56 | -121.63 | -79.62 | -115.17 | -129.06 | -148.70 | -117.40 | -234.34 | -307.44 | -363.45 | -321.15 | -116.94 | -108.64 | -95.56 | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.0 | 2.1 | 2.5 | 3.0 | 3.0 | 2.1 | 2.5 | 4.3 | 4.6 | - | 4.3 | 4.5 | 5.5 | 6.8 | 5.5 | 5.3 | 5.5 | 6.9 | 6.9 | 7.7 | 9.9 | 12.5 | 9.8 | 9.8 | 9.8 | 9.8 | 5.6 | 5.6 | 5.6 | 5.6 | 5.2 | 5.2 | 5.2 | 5.2 | 3.9 | 3.9 | 3.9 | 3.9 | 3.7 | 3.7 | 3.7 | 3.7 | 3.6 | 3.6 | 3.6 | 3.6 | 3.0 | 3.0 | 3.0 | 3.0 | 13.2 | 13.2 | 13.2 | 13.2 | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.2 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.2 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.2 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Matinas BioPharma Holdings, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Vanda Pharmaceuticals
VNDA
|
$ 4.01 | -3.84 % | $ 236 M |  USA |
 |
Johnson & Johnson
JNJ
|
$ 257.78 | -0.6 % | $ 621 B | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.63 | 4.61 % | $ 38.7 M | USA |
 |
Viridian Therapeutics
VRDN
|
$ 23.01 | 2.59 % | $ 2.34 B | USA |
 |
Verastem
VSTM
|
$ 9.21 | -1.39 % | $ 638 M | USA |
 |
VistaGen Therapeutics
VTGN
|
$ 0.19 | -2.12 % | $ 7.23 M | USA |
 |
vTv Therapeutics
VTVT
|
$ 27.77 | -0.27 % | $ 110 M | USA |
 |
Genprex
GNPX
|
$ 2.05 | -3.76 % | $ 1.91 M | USA |
 |
Voyager Therapeutics
VYGR
|
$ 2.02 | -7.76 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 6.4 | -0.31 % | $ 190 M | USA |
 |
Halozyme Therapeutics
HALO
|
$ 124.83 | 0.37 % | $ 15 B | USA |
 |
Kura Oncology
KURA
|
$ 9.88 | -1.0 % | $ 866 M | USA |
 |
Arvinas
ARVN
|
$ 7.56 | -1.37 % | $ 536 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.62 | -2.41 % | $ 431 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 67.74 | 0.28 % | $ 13 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
$ 38.31 | -1.01 % | $ 2.2 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 8.18 | 3.81 % | $ 125 M |  Australia |
 |
CNS Pharmaceuticals
CNSP
|
$ 4.83 | -3.31 % | $ 2.14 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | USA |
 |
MacroGenics
MGNX
|
$ 3.59 | 2.87 % | $ 227 M | USA |
 |
iBio
IBIO
|
$ 0.84 | 2.31 % | $ 87.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 62.86 | -1.7 % | $ 7.55 M | USA |
 |
Immunome
IMNM
|
$ 18.0 | 0.45 % | $ 1.57 B | USA |
 |
Immuron Limited
IMRN
|
$ 0.97 | -4.9 % | $ 224 M | Australia |
 |
Moderna
MRNA
|
$ 245.81 | 1.54 % | $ 95.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.36 | 1.49 % | $ 5.66 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.61 | 0.62 % | $ 39.9 M | USA |
 |
Novo Nordisk A/S
NVO
|
$ 39.06 | -0.71 % | $ 174 B |  Danmark |
 |
Inovio Pharmaceuticals
INO
|
$ 0.8 | -21.26 % | $ 37.5 M | USA |
 |
Insmed Incorporated
INSM
|
$ 94.04 | -1.7 % | $ 18.7 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.75 | -0.51 % | $ 760 M | USA |
 |
Biogen
BIIB
|
$ 240.98 | -0.87 % | $ 35.3 B | USA |
 |
BioVie
BIVI
|
$ 1.26 | 1.61 % | $ 1.86 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 44.27 | -2.49 % | $ 7.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.57 | -0.51 % | $ 141 M |  France |
 |
NextCure
NXTC
|
$ 5.42 | -0.46 % | $ 15.4 M | USA |
 |
BeyondSpring
BYSI
|
$ 0.5 | -5.13 % | $ 20.6 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 5.88 | -11.04 % | $ 273 M | USA |
 |
Vaxcyte
PCVX
|
$ 63.23 | -4.53 % | $ 8.6 B | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.51 | 2.57 % | $ 48.9 M | Canada |
 |
Outlook Therapeutics
OTLK
|
$ 0.56 | 7.94 % | $ 19.5 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.37 | -1.46 % | $ 568 M |  Singapore |
 |
Passage Bio
PASG
|
$ 3.59 | -0.28 % | $ 11.5 M | USA |
 |
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 83.44 | -1.92 % | $ 4.19 B | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.66 | -2.92 % | $ 163 M | USA |
|
Immatics N.V.
IMTX
|
$ 7.69 | 2.4 % | $ 941 M |  Germany |
 |
Immunic
IMUX
|
$ 7.48 | 0.94 % | $ 1.16 B | USA |
 |
Immunovant
IMVT
|
$ 28.38 | -0.73 % | $ 5.18 B | USA |
 |
MediciNova
MNOV
|
$ 1.41 | 3.68 % | $ 69.2 M | USA |